An Innovate UK-backed COVID-19 immunity and vaccination passport has entered its live testing phase.
The system has been developed by British firms Mvine and iProov.
The Mvine-iProov passport enables a person’s test result or vaccination status to be registered and proved without disclosing their identity, and without the need for extensive new infrastructure.
It will now be tested by directors of public health within the NHS. Mvine and iProov aim to complete two trials by 31 March 2021, with the hope of giving directors across the country the confidence to deploy the passport at scale.
Frank Joshi, director at Mvine, said: “Without the need for an extensive new infrastructure, the directors of public health will learn how our innovation is used to promote public health and protect citizen privacy.
“Unlike some other digital solutions for COVID-19, this technology reduces the burden on frontline services and cost-effectively assures a secure and safe way to enable the return to work, return to school and return to the kind of life that people want to lead.”
Andrew Bud, CEO at iProov, added: “Ensuring consumer trust, security and privacy is essential to the success of projects in this space. iProov enables all three.
“Our Genuine presence assurance technology secures the link between the citizen and Mvine’s test status solution in this project, which we think can make an important contribution to forming the national response to the COVID-19 crisis.”
The companies received a total of £75,000 from Innovate UK following a call for ideas in April 2020.